Jpmorgan Chase & CO Equillium, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Equillium, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 43 shares of EQ stock, worth $26. This represents 0.0% of its overall portfolio holdings.
Number of Shares
43
Previous 43
-0.0%
Holding current value
$26
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding EQ
# of Institutions
27Shares Held
11.3MCall Options Held
0Put Options Held
0-
Decheng Capital LLC Menlo Park, CA4.45MShares$2.71 Million0.88% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.45MShares$2.71 Million1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA842KShares$513,5880.0% of portfolio
-
Cota Capital Management, LLC San Francisco, CA562KShares$342,9891.86% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny321KShares$195,9150.0% of portfolio
About Equillium, Inc.
- Ticker EQ
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,352,100
- Market Cap $21M
- Description
- Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...